12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ryzodeg insulin degludec/insulin aspart regulatory update

EMA's CHMP recommended approval of an MAA from Novo Nordisk for Ryzodeg insulin degludec/insulin aspart to treat Type I and...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >